Antares Pharma to Present at the 2015 RBC Capital Markets' Global Healthcare Conference

EWING, N.J.--(BUSINESS WIRE)--

Antares Pharma, Inc. ATRS today announced that Eamonn P. Hobbs, President and Chief Executive Officer, will present a corporate overview at the RBC Capital Markets' Global Healthcare Conference on Wednesday February 25, 2015 at 4:05 pm Eastern Time.

A live webcast of the presentation will be available via the "Investor Information/Webcasts" page of the Antares website, www.antarespharma.com. A replay of the webcast will also be archived on Antares' website for 90 days following the presentation.

About Antares Pharma

Antares Pharma focuses on self-administered parenteral pharmaceutical products. The Company markets OTREXUP™ (methotrexate) injection for subcutaneous use in the treatment of adults with severe active rheumatoid arthritis and children with active polyarticular juvenile idiopathic arthritis. LEO Pharma markets OTREXUP™ to dermatologists for adults with severe recalcitrant psoriasis. Antares Pharma is also developing QuickShot^® Testosterone for testosterone replacement therapy, and VIBEX^® Sumatriptan for the acute treatment of migraines. The Company's technology platforms include VIBEX^® disposable auto injectors, disposable multi-use pen injectors and reusable needle-free injectors. Antares Pharma has a multi-product deal with Teva Pharmaceutical Industries, Ltd. that includes VIBEX^® epinephrine, exenatide multi-dose pen, and another undisclosed multi-dose pen. Our reusable needle-free injector for use with human growth hormone (hGH) is sold worldwide by Ferring Pharmaceuticals BV.